Cotargeting of BCL2 with Venetoclax and MCL1 with S63845 Is Synthetically Lethal In Vivo in Relapsed Mantle Cell Lymphoma

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F86652036%3A_____%2F19%3A00521329" target="_blank" >RIV/86652036:_____/19:00521329 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11110/19:10395615 RIV/00216208:11130/19:10395615 RIV/61384399:31140/19:00053787 RIV/00064203:_____/19:10395615 and 2 more
Result on the web
<a href="https://clincancerres.aacrjournals.org/content/25/14/4455" target="_blank" >https://clincancerres.aacrjournals.org/content/25/14/4455</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1158/1078-0432.CCR-18-3275" target="_blank" >10.1158/1078-0432.CCR-18-3275</a>

Result language
angličtina
Original language name
Cotargeting of BCL2 with Venetoclax and MCL1 with S63845 Is Synthetically Lethal In Vivo in Relapsed Mantle Cell Lymphoma
Original language description
Purpose: Mantle cell lymphoma (MCL) is an aggressive subtype of B-cell non-Hodgkin lymphomas characterized by (over) expression of BCL2. A BCL2-targeting drug, venetoclax, has promising anticancer activity in MCL. We analyzed molecular mechanisms of venetoclax resistance in MCL cells and tested strategies to overcome it.
Czech name
—
Czech description
—

Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30204 - Oncology

Project
<a href="/en/project/NV17-28980A" target="_blank" >NV17-28980A: New prognostic and predictive markers in patients with mantle cell lymphoma at diagnosis and on treatment</a><br>
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2019
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)